Overview

Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.
Phase:
Phase 4
Details
Lead Sponsor:
Nova Scotia Health Authority
Collaborator:
Nova Scotia Health Research Foundation
Treatments:
Amlodipine
Atenolol
Hydrochlorothiazide
Quinapril
Terazosin